Pharm prime vendor fleet
Ended Awarded Last action
- Contract number
- SPE2DU26F0G80
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,373
Award facts
- Contract value 100% obligated
- $1,373.05 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,373.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This firm fixed-price delivery order, issued on December 2, 2025, with an ultimate completion date of December 3, 2025, represents one of numerous purchase orders DMS has received under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The delivery order carries no set-aside designation, reflecting DMS's competitive capability in unrestricted federal procurement. DMS will supply pharmaceutical products and medical consumables to support Department of Defense healthcare operations, consistent with its role as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy.
DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) under the PPV-G GEN V program (contract SPE2DR), awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. This IDC encompasses a 30-month base period with three optional 30-month renewals and authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty medical consumables. The company's product portfolio spans oncology treatments, immunosuppressants, emergency medications, surgical products, and routine pharmaceuticals, positioning DMS as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DU26F0G80?
SPE2DU26F0G80 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 2, 2025.
How much is contract SPE2DU26F0G80 worth?
The government has obligated $1,373 on SPE2DU26F0G80.
Is contract SPE2DU26F0G80 an order under another contract?
Yes. SPE2DU26F0G80 is a delivery order under SPE2DU25D9803, an indefinite delivery contract.
Was contract SPE2DU26F0G80 competed?
The extent of competition for SPE2DU26F0G80 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award